Analysts Offer Insights on Healthcare Companies: Otonomy (NASDAQ: OTIC) and Eloxx Pharmaceuticals (NASDAQ: ELOX)

By Austin Angelo

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Otonomy (OTICResearch Report) and Eloxx Pharmaceuticals (ELOXResearch Report).

Otonomy (OTIC)

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Otonomy, with a price target of $8.00. The company’s shares closed last Monday at $2.29.

According to TipRanks.com, Livnat is a 5-star analyst with an average return of 13.8% and a 60.1% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Zynerba Pharmaceuticals, and Verrica Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Otonomy with a $8.00 average price target.

See today’s analyst top recommended stocks >>

Eloxx Pharmaceuticals (ELOX)

H.C. Wainwright analyst Andrew Fein reiterated a Hold rating on Eloxx Pharmaceuticals today and set a price target of $10.00. The company’s shares closed last Monday at $6.55.

According to TipRanks.com, Fein is a 3-star analyst with an average return of 0.7% and a 42.4% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.

Eloxx Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $10.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.